Track the 스피어 share price and the full directors' dealings record of the company, a listed equity based in South Korea. Shares are quoted on KR KR, under the supervision of DART (FSS). Operating in the Health Care sector, 스피어 has recorded 70 public disclosures. Market capitalisation: €803.6bn. The latest transaction was disclosed on 11 May 2026 (Sale). Among the most active insiders: 한종현. Every trade is free.
70
Insider Decl.
n/a
Thresholds
n/a
29 ops.
Buy Volume
€639,870
17 ops.
Sell Volume
33Σ signal
Buys n/a€639,870 Sells
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 18,428 of 28,169 companies
41.9
score / 100
Value
32
Quality
52
FCF yld-1.4%
Earn yld0.0%
EV/EBITDA·
ROE55%
Gross mgn18%
Net mgn0.2%
Debt/EBITDA1.4x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
스피어 is a company operating in the healthcare and pharmaceutical sector, listed on the XKRX market. It focuses on developing innovative solutions to enhance healthcare.